A Study of Belcesiran in Patients With A1ATD-Associated Liver Disease

Related Clinical Trial
Functional and Structural Lung Imaging in Chronic Obstructive Pulmonary Disease A Study of Belcesiran in Patients With A1ATD-Associated Liver Disease A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin Deficiency Evaluation of the Efficacy and Safety of VX-864 in Subjects With the PiZZ Genotype A Single Ascending and Repeated Dose Study of Oral ZF874 in Healthy Volunteers and PiMZ Subjects ARALAST NP Alpha-1 Lung Density Chronic Obstructive Pulmonary Disease-Emphysema (COPD-E) Study Early Access Program Using Alpha 1 Antitrypsin Infusion for Patients With Steroid Refractory Acute GvHD After Hematopoietic Stem Cell Transplantation (HSCT) Characterization of the Pathobiology of Early Lung Destruction in Alpha 1-Antitrypsin Deficient Individuals COPD Exacerbation Blood and Urine Biomarkers Study Alpha-1 Carrier Genomics Study Evaluation of the Efficacy and Safety of VX-814 in Subjects With the PiZZ Genotype Study of ARO-AAT in Normal Adult Volunteers Safety Study of Alfalastin (Human Alpha-1 Antitrypsin) Administered at Home AL1TER™: Alpha-1 Therapy, Evaluation, and Research Patient Registry Respreeza® Self-administration and Learning Program (AmAREtTI Study) Experimental Gene Transfer Procedure to Treat Alpha 1-Antitrypsin (AAT) Deficiency Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo. Environment Effect on Six-Minute Walk Test Performance Alpha-1 Foundation DNA and Tissue Bank Alpha1-antitrypsin Deficiency Registry Alpha-1 Research Registry Stage 1 Study of ARALAST NP and GLASSIA in A1PI Deficiency Alpha-1 Coded Testing(ACT) Study Long-Term Follow-up Study of ADVM-043 Safety Dose Finding Study of ADVM-043 Gene Therapy to Treat Alpha-1 Antitrypsin (A1AT) Deficiency 4-PBA: Will it Increase the Level of Alpha 1-Antitrypsin(AAT) in Persons With AAT Deficiency? Experimental Gene Transfer Procedure to Treat Alpha 1-Antitrypsin Deficiency Management of Patients With Alpha-1 Antitrypsin Deficiency Associated Emphysema Phase II, Safety and Efficacy Study of Kamada-alpha-1-antitrypsin (AAT) for Inhalation” EARCO REGISTRY. History Of Patients With Alpha-1 Antitrypsin GLASSIA Safety, Immunogenicity, and Bronchoalveolar Lavage Study Safety, Tolerability and Effect of ARC-AAT Injection on Circulating and Intrahepatic Alpha-1 Antitrypsin Levels Efficacy/Safety of HA Inhalation Solution for Hereditary Emphysema in Patients With Alpha-1 Antitrypsin Deficiency Safety and Pharmacokinetics of Alpha-1 MP in Patients With Alpha1-Antitrypsin Deficiency Phase II/III Study of an Alpha-1 Proteinase Inhibitor (Kamada-API) in Individuals With Alpha-1 Antitrypsin Deficiency Study of the Effect of Aerosolized, Recombinant Alpha 1-Antitrypsin on Epithelial Lining Fluid Analytes in Subjects With Alpha 1-Antitrypsin Deficiency Alvelestat (MPH966) for the Treatment of ALpha-1 ANTitrypsin Deficiency The Safety and Tolerability of Alpha-1 Modified Process (MP) In Subjects With Alpha-1-antitrypsin (AAT) Deficiency Lung Volume Reduction Coils for Emphysema in Alpha-1 Antitrypsin Deficiency Study of Genotype and Phenotype in Patients With Alpha 1-Antitrypsin Deficiency Alpha-1 Foundation Research Registry Targeting Pulmonary Perfusion in Alpha-1 Antitrypsin Deficiency Effects of Exercise Training in Chronic Obstructive Pulmonary Disease Versus Alpha-1-Antitrypsin-deficiency-patients Evaluate Efficacy and Safety of “Kamada-AAT for Inhalation” in Patients With AATD A Study of DCR-A1AT in Healthy Adult Volunteers and Patients With A1ATD-Associated Liver Disease Safety & Efficacy Study of rAAV1-CB-hAAT for Alpha-1 Antitrypsin Deficiency Effects of Different Exercise Training Modalities in Alpha-1 Antitrypsin Deficiency Patients Safety Study of an Aerosolized, Recombinant Alpha 1-Antitrypsin in Subjects With Alpha 1-Antitrypsin Deficiency Study Comparing Weekly Intravenous Administration of OctaAlpha1 With a Marketed Preparation Glassia® in Subjects With Alpha-1-antitrypsin Deficiency Long-term Safety of Alpha1-Proteinase Inhibitor (Human) in Japanese Subjects With Alpha1 Antitrypsin Deficiency (GTI1401-OLE) Efficacy and Safety Study of Augmentation Therapy With ARALAST Fraction IV-1 (Human Alpha 1 – Proteinase Inhibitor) Aralast alpha1-proteinase Inhibitor Surveillance Study Pharmacokinetic Study of ARALAST (Human Alpha1- PI) The Use of High Resolution Chest Computed Tomography in Alpha-1 Antitrypsin Deficiency Prevalence of Alpha-1 Antitrypsin Deficiency in Chronic Obstructive Pulmonary Disease (COPD) Comparison of Pharmacokinetic, Safety, Tolerability of Alpha-1 MP and Prolastin In Alpha1-antitrypsin Deficient Adults Phase 1 Study to Assess the Safety, PK and PD of INBRX-101 in Adults With Alpha-1 Antitrypsin Deficiency Safety and Pharmacokinetics of Alpha-1 Proteinase Inhibitor in Subjects With Alpha1-Antitrypsin Deficiency The Impact of Delayed Diagnosis of Alpha-1 Antitrypsin Deficiency Epigenetic Regulation of Immunity in Alpha-1 Anti-trypsin Deficiency Microbioma in Sputa From COPD With Alpha-1 Antitrypsin Deficiency A Study of ARC-AAT in Healthy Volunteer Subjects and Patients With Alpha-1 Antitrypsin Deficiency (AATD) A Study to Assess Safety and PK of Liquid Alpha₁-Proteinase Inhibitor (Human) in Treating Alpha₁-Antitrypsin Deficiency

Brief Title

A Study of Belcesiran in Patients With A1ATD-Associated Liver Disease

Official Title

A Phase 2a, Randomized, Double-blind, Placebo Controlled, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of Belcesiran in Patients With PiZZ Alpha-1 Antitrypsin Deficiency

Brief Summary

      This is a multiple dose, randomized, placebo-controlled, double-blind study of belcesiran to
      evaluate the safety, tolerability, PK, and PD in adult patients with PiZZ A1ATD-associated
      liver disease.

      The study will be conducted in 2 parallel cohorts. A total of up to 27 participants may be
      enrolled in a single cohort. The 2 cohorts are differentiated only by the duration of the
      treatment period, the number of doses administered, and the timing of the end-of-treatment
      (EOT) liver biopsy. Participants in Cohort 1 will undergo EOT biopsy at 24 weeks, and
      participants in Cohort 2 will undergo EOT biopsy at 48 weeks.
    

Detailed Description

      A1ATD-associated liver disease is a progressive Alpha-1 Antitrypsin-Deficiency Associated
      Liver Disease condition resulting in liver fibrosis, cirrhosis, and hepatocellular carcinoma.
      The lack of functional A1AT in individuals with the PiZZ genotype, in conjunction with other
      precipitating factors, can lead to unchecked activity of neutrophil elastases in the alveoli;
      causing emphysema and chronic obstructive pulmonary disease (COPD). This loss-of-function
      mechanism can be addressed with intravenous augmentation therapy, which aims to substitute
      the missing A1AT by infusing alpha-1 proteinase inhibitor (A1PI), purified from pooled human
      plasma.

      While augmentation therapy can address the loss of A1AT in the lung, no treatment exists for
      the associated liver disease.

      Given the severity of the disease, with approximately 10% of affected patients developing
      liver cirrhosis and a subgroup of those patients in need of liver transplantation, and the
      lack of an effective treatment that addresses the toxic hepatic "gain-of-function" mechanism,
      there is an urgent unmet medical need to develop a therapy that can help this particular
      patient population.
    

Study Phase

Phase 2

Study Type

Interventional


Primary Outcome

The incidence of adverse events (AE), serious adverse events (SAE), and AE leading to study drug discontinuation.

Secondary Outcome

 Plasma concentration of Belcesiran on Day 1

Condition

Alpha 1-Antitrypsin Deficiency

Intervention

belcesiran

Study Arms / Comparison Groups

 Experimental: belcesiran
Description:  Patients diagnosed with A1ATD-Associated Liver Disease will be administered belcesiran.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

54

Start Date

February 12, 2021

Completion Date

December 1, 2023

Primary Completion Date

December 1, 2022

Eligibility Criteria

        Inclusion Criteria:

          -  18 to 70 years, inclusive. Female participants must be either surgically sterile or
             postmenopausal. No women of childbearing potential are eligible for enrollment.

          -  Documented diagnosis of PiZZ-type A1ATD, confirmed by genotyping. Historical
             genotyping data may be used, if available.

          -  A1ATD-associated liver disease documented by liver biopsy.

          -  Consent to undergo paired liver biopsies, one at Screening and one at either 24 weeks
             or 48 weeks of the first dose of the study intervention

          -  Lung, renal and liver function within acceptable limits

          -  Capable of giving signed informed consent, which includes compliance with the
             requirements and restrictions listed in the ICF and in this protocol.

        Exclusion Criteria:

          -  Presence of any condition or comorbidities that would interfere with study compliance
             or data interpretation or potentially affect patient safety including, but not
             restricted to:

          -  Severe intercurrent illness.

          -  History of chronic liver disease from any cause other than PiZZ-type A1ATD,

          -  A1AT augmentation therapy in the 6 months prior to Screening

          -  Routine use of acetaminophen/paracetamol

          -  Use of systemically acting steroids in the month prior to Screening and throughout the
             study period.

          -  Participation in any clinical study in which they received an IMP within 4 months
             before Screening
      

Gender

All

Ages

18 Years - 70 Years

Accepts Healthy Volunteers

No

Contacts

Hardean Achneck, MD, 617-621-8097, [email protected]

Location Countries

New Zealand

Location Countries

New Zealand

Administrative Informations


NCT ID

NCT04764448

Organization ID

DCR-A1AT-201


Responsible Party

Sponsor

Study Sponsor

Dicerna Pharmaceuticals, Inc.


Study Sponsor

Hardean Achneck, MD, Study Director, Dicerna Pharmaceuticals


Verification Date

February 2021